AI-driven MedTech firm Renalytix AI has results published

Kidney disease is one of the most common and costly chronic medical conditions globally.

AI-enabled clinical diagnostics firm Renalytix AI has announced its positive results have been published in the Journal of American Society of Nephrology.

The firm, which was formed in March 2018 as a wholly-owned subsidiary of healthcare group EKF Diagnostics, uses large electronic health records, predictive blood-based biomarkers and other information for analysis by learning computer algorithms.

Its published results demonstrate that a blood test can diagnose kidney rejection before clinical signs of kidney damage, which could be used to tailor immunosuppressive therapy.

The Cardiff-headquartered, company develops its technology to treat the disease, and support in diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery.

The results demonstrate key information can be provided to a transplant clinician without the need for an invasive kidney biopsy.

"In transplant, the inability to accurately identify rejection before any clinical signs appear has a significant impact on therapeutic management and long-term viability of the transplanted kidney,” said Dr. Barbara Murphy, Non-Executive Director of RenalytixAI, Dean for Clinical Integration and Population Health, Professor and System Chair Medicine and Nephrology, at the Icahn School of Medicine at Mount Sinai (ISMMS).

“These study results demonstrate that non-invasive measurements may be used to stratify patients immunologically so that immunosuppressive therapy can be tailored to the individual patient needs."

The firm now intends to begin larger scale clinical validation of the results, with a formal launch as a laboratory developed test through its New York City clinical laboratory facility expected in 2020.

Products under development from the portfolio are anticipated to be part of the extended RenalytixAI pipeline following the introduction of KidneyIntelX in 2019 for the diagnosis of fast-progressing chronic kidney disease.

Last week the firm said it was preparing to roll out KidneyIntelX in the United States.